Investment strategy

Parkwalk invests in high growth British companies, seeking to utilise and commercialise some of the £4.5bn  annual publicly-funded research investment made through our Universities and other R&D intensive institutions.

The University of Cambridge alone has spun-out 15 companies that now have a market capitalisation of over $1bn, of which two are over $10bn.

Parkwalk Funds are risk venture capital funds seeking tax free capital appreciation through the EIS. To help mitigate these risks we believe we have strong selection criteria and investment processes and procedures.

The Opportunities Fund (similarly to Tech Funds I-VII) generally co-invests with other large VCs who have the financial ability to cornerstone future funding rounds where necessary.

Parkwalk UK Tech Funds I & II have both returned, in cash, more to investors than the total cost of their subscriptions into each Fund. Funds III, IV, V and the Opportunities Fund have all also had cash distributions from a successful exit.

Sector Spread

The Opportunities EIS Fund and each of our UK Tech Funds I – VII have invested across a spread of technologies and innovation ranging from high-tech through to software, algorithms, chemicals, energy, renewables, materials, med-tech, clean-tech, genomics – the list is extremely varied.

What they all have in common is commerciality and the potential to generate successful returns.

Maturity Spread

The Opportunities EIS Fund and each of our UK Tech Funds I – VII also have a spread of company maturities from early stage through to AIM-listed, with each Fund having at least one ‘pre-IPO’ or  AIM-listed stock.
The University of Cambridge Enterprise Funds, the University of Oxford Innovation Funds and the University of Bristol Enterprise Funds generally make more early-stage investments.

Management Teams

Parkwalk portfolio companies have commercial management teams sourced from relevant industry to commerialise a particular patent, know-how or process.

Generally, the researcher behind the project becomes Chief Scientific Officer or Chief Technology Officer while new management takes the product to market.

Focused Strategy
Experienced Management
Unparalleled Access
Follow-On Funding
Parkwalk Search
Integrity and Transparency
Governance
Risk Management
Partners
Investor Services

Independent Reviews

Parkwalk Funds have been reviewed by both the Tax Efficient Review and the Tax Shelter Report.
Click here to contact the Parkwalk funds team to request further details or call us on 020 7759 2285.

 

Email Signature Logos